mites folliculitis
Conditions
Interventions
1:ornidazole (0.5 g/time, t.d., per os) and CBI(1 mL, i.m.)
2:ornidazole (0.5 g/time, t.d., per os) and ebastine (10 mg, o.d., per os)
3:metronidazole (0.2 g/time, q.d.s., per os) and CBI(1 mL, i.m.)
4:metronidazole (0.2 g/time, q.d.s., per os) and ebastine (10 mg, o.d., per os)
Sponsors
Department of Dermatology, Lanzhou General Hospital of Lanzhou Military Area Command
Eligibility
Sex/Gender
All
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: All patients had normal liver function, and no history of drug allergy, tumors, or a diagnosis and treatment of mites folliculitis. The female patients had normal menstruation. All enrolled patients had their facial skin checked for the presence of live mites by microscopy.
Exclusion criteria
Exclusion criteria: Under age 20, or older than 45; Pregnant women and nursing mothers; With cardiovascular, liver, kidney and hematopoietic system and so on patients with severe primary diseases; Patients with psychosis, oncosis. Women's menstrual abnormalities, patients with history of menopause and the history of menstrual disorders; Before ever being diagnosed and treated of mites folliculitis; Always be allergic to ornidazole, compound betamethasone injection and recombinant bovine basic fibroblast growth factor gel.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of cases of detect the mites; | — |
Countries
China
Contacts
Public ContactYang Luo
Outcome results
None listed